Two Years of Tamoxifen Offers Long-Term Survival Benefit

This article originally appeared here.
Share this content:
Two Years of Tamoxifen Offers Long-Term Survival Benefit
Two Years of Tamoxifen Offers Long-Term Survival Benefit

THURSDAY, May 12, 2016 (HealthDay News) -- For premenopausal women with breast cancer, two years of tamoxifen is associated with long-term survival benefit, according to a study published online May 9 in the Journal of Clinical Oncology.

Maria Ekholm, M.D., from Lund University in Sweden, and colleagues randomized premenopausal patients with breast cancer to two years of tamoxifen (276 patients) or no systemic treatment (288 patients). The patients were followed for a median of 26.3 years for end points of cumulative mortality (CM) and cumulative breast cancer-related mortality (CBCM).

The researchers found that tamoxifen was associated with a marginal reduction in CM (hazard ratio, 0.77; 95 percent confidence interval, 0.58 to 1.03) and a significant reduction in CBCM (hazard ratio, 0.73; 95 percent confidence interval, 0.53 to 0.99) in patients with estrogen receptor-positive tumors. The effect varied over time for CM (hazard ratios: years 0 to 5, 1.05 [95 percent CI, 0.64 to 1.73]; >5 to 15, 0.58 [95 percent CI, 0.37 to 0.91]; and >15 years, 0.82 [95 percent CI, 0.48 to 1.42]) and for CBCM (hazard ratios: years 0 to 5, 1.09 [95 percent CI, 0.65 to 1.82]; >5 to 15, 0.53 [95 percent CI, 0.33 to 0.86]; and >15 years, 0.72 [95 percent CI, 0.36 to 1.44]).

"Two years of adjuvant tamoxifen resulted in a long-term survival benefit in premenopausal patients with estrogen receptor-positive primary breast cancer," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »